Leveraging Data to Improve Clinical Care
Goshua Lab at Yale School of Medicine
May 1, 2023
Christina Waldron awarded ASH HONORS
January 9, 2023
Ayesha Butt is awarded a 2023 Highlights of ASH selection for ASH Oral
December 21, 2022
Sickle Cell Cure will be Cost-Effective if Health Disparities Considered -Study Finds
Our Collaborators
We are the spoke of a collaborative research hub that include experts from leading health care institutions around the world.
.png)
Aligning Clinical Treatment Strategies with Value and Equity to Improve Health Care Performance
The US continues to rank #1/11 in health care spending and #11/11 in healthcare performance. We consistently pay more for less health. The Goshua Lab fuses state-of-the-art in quantitative decision science with clinical expertise to address this value lost, with a particular focus on rare hematologic-oncologic diseases. Our analytic lens includes both conventional value (i.e., cost-benefit) and equity-informed analyses to inform stakeholders’ decision-making on resource allocation in health care.
Our Work
Source: Mirror, Mirror 2021: Reflecting Poorly, The Commonwealth Fund
Selected Recognitions
Our work has been recognized by premier national organizations and conferences
Most cited original research manuscript in
The Lancet Hematology
Oral Presentations
(11 ASH, 1 EHA, 2 SMDM)
Trending manuscript globally on PubMed (Blood)
ASH Press Program Selections
(from >5000 abstracts)
Distributional cost-effectiveness of equity-enhancing gene therapy in sickle cell disease in the United States
Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A
Annals of Internal Medicine
2023
May
FEATURED
Conference Recognitions: ASH Oral and ASH Press Program Selection (1 of 2 in 2022)
Practical impact: For treatment funding decisions, even if gene therapy is cost-ineffective by conventional CEA standards, it is an equitable therapy per DCEA standards in the United States for patients with sickle cell disease.
.png)
Distributional cost-effectiveness of equity-enhancing gene therapy in sickle cell disease in the United States
Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A
Annals of Internal Medicine
2023
May
FEATURED
Conference Recognitions: ASH Oral and ASH Press Program Selection (1 of 2 in 2022)
Practical impact: For treatment funding decisions, even if gene therapy is cost-ineffective by conventional CEA standards, it is an equitable therapy per DCEA standards in the United States for patients with sickle cell disease.
Featured Publications
Distributional cost-effectiveness of equity-enhancing gene therapy in sickle cell disease in the United States
Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A
Annals of Internal Medicine
2023
May
FEATURED
Conference Recognitions: ASH Oral and ASH Press Program Selection (1 of 2 in 2022)
Practical impact: For treatment funding decisions, even if gene therapy is cost-ineffective by conventional CEA standards, it is an equitable therapy per DCEA standards in the United States for patients with sickle cell disease.
Featured Publications
Featured Publications
Distributional cost-effectiveness of equity-enhancing gene therapy in sickle cell disease in the United States
Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A
Annals of Internal Medicine
2023
May
FEATURED
Conference Recognitions: ASH Oral and ASH Press Program Selection (1 of 2 in 2022)
Practical impact: For treatment funding decisions, even if gene therapy is cost-ineffective by conventional CEA standards, it is an equitable therapy per DCEA standards in the United States for patients with sickle cell disease.
Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia
Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A
American Journal of Hematology
2023
January
FEATURED
Conference Recognitions: ASH Oral, ASH Abstract Achievement Award (2021 ASH Trainee Recipient: Dr. Goshua), Best of ASH for North America, Best of ASH (HTRS), 2022 American Journal of Hematology Young Investigator Award Paper of the Year [Finalist]
Practical impact: Fills gap in the 2019 ASH ITP Guidelines and shows that the theoretical concerns about splenectomy tripartite risks that led to its decreased utilization in the United States across 2000-2020 do not outweigh treatment benefit. In addition, for patients whose values and preferences align with surgery, splenectomy-early strategies are the cost-effective strategies.
.png)
Apixaban at apex? Aligning drug pricing with value in cancer-associated thrombosis
Ito S and Goshua G
Annals of Internal Medicine
2023
January
FEATURED
Conference Recognitions: ASH Oral and ASH Press Program Selection (1 of 2 in 2022)
Practical impact: For treatment funding decisions, even if gene therapy is cost-ineffective by conventional CEA standards, it is an equitable therapy per DCEA standards in the United States for patients with sickle cell disease.
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickon JE, Tormey C, Bendapudi PK, Lee AI
Blood
2021
February
FEATURED
Conference Recognitions: ASH Oral, Best of ASH (HTRS), ASH Abstract Achievement Award (2020 ASH Trainee Recipient: Dr. Goshua). #1 global trend manuscript (PubMed December 2020)
Practical impact: First health economic evidence of robust caplacizumab cost-ineffectiveness in best-case base-case (even-if analysis) with subsequent 2022 international debates at ISTH (London) and ASH (New Orleans; Education Spotlight).
.png)
Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura
Goshua G, Gokhale A, Hendrickson JE, Tormey C, Lee AI
Blood Advances
2020
February
FEATURED
.png)